• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织蛋白酶S通过基质衍生的血管生成因子控制血管生成和肿瘤生长。

Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors.

作者信息

Wang Bing, Sun Jiusong, Kitamoto Shiro, Yang Min, Grubb Anders, Chapman Harold A, Kalluri Raghu, Shi Guo-Ping

机构信息

Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 77 Ave. Louis Pasteur, Boston, MA 02115, USA.

出版信息

J Biol Chem. 2006 Mar 3;281(9):6020-9. doi: 10.1074/jbc.M509134200. Epub 2005 Dec 19.

DOI:10.1074/jbc.M509134200
PMID:16365041
Abstract

The cysteine protease cathepsin S is highly expressed in malignant tissues. By using a mouse model of multistage murine pancreatic islet cell carcinogenesis in which cysteine cathepsin activity has been functionally implicated, we demonstrated that selective cathepsin S deficiency impaired angiogenesis and tumor cell proliferation, thereby impairing angiogenic islet formation and the growth of solid tumors, whereas the absence of its endogenous inhibitor cystatin C resulted in opposite phenotypes. Although mitogenic vascular endothelial growth factor, transforming growth factor-beta1, and the anti-angiogenic endostatin levels in either serum or carcinoma tissue extracts did not change in cathepsin S- or cystatin C-null mice, tumor tissue basic fibroblast growth factor and serum type 1 insulin growth factor levels were higher in cystatin C-null mice, and serum type 1 insulin growth factor levels were also increased in cathepsin S-null mice. Furthermore, cathepsin S affected the production of type IV collagen-derived anti-angiogenic peptides and the generation of bioactive pro-angiogenic gamma2 fragments from laminin-5, revealing a functional role for cathepsin S in angiogenesis and neoplastic progression.

摘要

半胱氨酸蛋白酶组织蛋白酶S在恶性组织中高表达。利用一个多阶段小鼠胰岛细胞癌变的小鼠模型(其中半胱氨酸组织蛋白酶活性在功能上与之相关),我们证明,组织蛋白酶S的选择性缺乏会损害血管生成和肿瘤细胞增殖,从而损害血管生成性胰岛形成和实体瘤生长,而其内源性抑制剂胱抑素C的缺失则导致相反的表型。尽管在组织蛋白酶S基因敲除或胱抑素C基因敲除小鼠中,血清或癌组织提取物中的促有丝分裂血管内皮生长因子、转化生长因子-β1和抗血管生成内皮抑素水平没有变化,但胱抑素C基因敲除小鼠的肿瘤组织碱性成纤维细胞生长因子和血清1型胰岛素生长因子水平较高,组织蛋白酶S基因敲除小鼠的血清1型胰岛素生长因子水平也升高。此外,组织蛋白酶S影响IV型胶原衍生的抗血管生成肽的产生以及层粘连蛋白-5生物活性促血管生成γ2片段的生成,揭示了组织蛋白酶S在血管生成和肿瘤进展中的功能作用。

相似文献

1
Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors.组织蛋白酶S通过基质衍生的血管生成因子控制血管生成和肿瘤生长。
J Biol Chem. 2006 Mar 3;281(9):6020-9. doi: 10.1074/jbc.M509134200. Epub 2005 Dec 19.
2
Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.半胱氨酸蛋白酶抑制剂 C 缺乏促进 K14-HPV16 转基因小鼠的表皮发育不良。
PLoS One. 2010 Nov 15;5(11):e13973. doi: 10.1371/journal.pone.0013973.
3
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.半胱氨酸组织蛋白酶基因在多阶段肿瘤发生中的不同作用。
Genes Dev. 2006 Mar 1;20(5):543-56. doi: 10.1101/gad.1407406. Epub 2006 Feb 15.
4
Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin.半胱氨酸蛋白酶 S 和 L 调节人内皮抑素的抗血管生成活性。
J Biol Chem. 2011 Oct 28;286(43):37158-67. doi: 10.1074/jbc.M111.284869. Epub 2011 Sep 6.
5
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.平衡血管生成调节因子以特定阶段的方式控制癌症进展和存活的速度。
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9939-44. doi: 10.1073/pnas.1105041108. Epub 2011 May 27.
6
Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms.组织蛋白酶B、K和S在脑动脉瘤中表达,并促进脑动脉瘤的进展。
Stroke. 2008 Sep;39(9):2603-10. doi: 10.1161/STROKEAHA.107.513648. Epub 2008 Jul 17.
7
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.组织蛋白酶半胱氨酸蛋白酶是多阶段肿瘤发生过程中侵袭性生长和血管生成的效应因子。
Cancer Cell. 2004 May;5(5):443-53. doi: 10.1016/s1535-6108(04)00111-4.
8
rd1 Mouse retina shows an imbalance in the activity of cysteine protease cathepsins and their endogenous inhibitor cystatin C.rd1小鼠视网膜显示半胱氨酸蛋白酶组织蛋白酶与其内源性抑制剂胱抑素C的活性失衡。
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1089-96. doi: 10.1167/iovs.07-0549.
9
Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin.p53介导的肿瘤抑制作用部分是由内皮抑素和肿瘤抑素的抗血管生成活性介导的。
Sci STKE. 2006 Sep 26;2006(354):pe35. doi: 10.1126/stke.3542006pe35.
10
Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves.狭窄主动脉瓣中弹性蛋白酶组织蛋白酶S、K和V及其抑制剂胱抑素C的表达增加。
Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1791-8. doi: 10.1161/01.ATV.0000228824.01604.63. Epub 2006 May 25.

引用本文的文献

1
Exploring microRNA targeting as a promising approach for solid tumor treatment.探索将微小RNA靶向作为实体瘤治疗的一种有前景的方法。
Front Oncol. 2025 Jul 21;15:1570093. doi: 10.3389/fonc.2025.1570093. eCollection 2025.
2
Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer.揭示组织蛋白酶S在白细胞介素-7介导的抗肿瘤免疫中的调控机制,揭示了其对口腔癌的靶向治疗潜力。
J Biomed Sci. 2025 Jul 24;32(1):69. doi: 10.1186/s12929-025-01154-6.
3
Plasminogen Activator Inhibitor 1 Controls Abdominal Aortic Aneurism Formation via the Modulation of TGF-β/Smad2/3 Signaling in Mice.
纤溶酶原激活物抑制剂1通过调节小鼠TGF-β/Smad2/3信号通路控制腹主动脉瘤的形成。
FASEB J. 2025 May 15;39(9):e70562. doi: 10.1096/fj.202403133RR.
4
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers.组织蛋白酶:肿瘤生态系统中克服癌症的新兴靶点。
Semin Cancer Biol. 2025 Jul;112:150-166. doi: 10.1016/j.semcancer.2025.04.001. Epub 2025 Apr 12.
5
Targeted approach to determine the impact of cancer-associated protease variants.确定癌症相关蛋白酶变体影响的靶向方法。
Sci Adv. 2025 Feb 14;11(7):eadp5958. doi: 10.1126/sciadv.adp5958. Epub 2025 Feb 12.
6
Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy.溶酶体肽酶在生理和病理条件下的非经典、溶酶体外活性:癌症治疗的新临床机遇
Cells. 2025 Jan 7;14(2):68. doi: 10.3390/cells14020068.
7
Association between cathepsins and skin cancers: A bidirectional two-sample Mendelian randomization study.组织蛋白酶与皮肤癌的关联:一项双向两样本 Mendelian 随机化研究。
Skin Res Technol. 2024 Aug;30(8):e13905. doi: 10.1111/srt.13905.
8
Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.多中心蛋白质组学全基因组孟德尔随机化研究鉴定黑色素瘤和非黑色素瘤皮肤癌中的因果性血浆蛋白。
Commun Biol. 2024 Jul 13;7(1):857. doi: 10.1038/s42003-024-06538-2.
9
Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization.刺激响应性聚合物前药纳米载体的可逆失活自由基聚合。
Chem Soc Rev. 2024 Jun 17;53(12):6511-6567. doi: 10.1039/d2cs01060g.
10
Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.评估可变新抗原受体(vNARs)作为一种靶向组织蛋白酶S(CTSS)的新策略。
Front Pharmacol. 2023 Dec 5;14:1296567. doi: 10.3389/fphar.2023.1296567. eCollection 2023.